In current clinical trials approaches, common cancer-promoting regulators such as the WNT, cyclin-dependent kinases and Ak strain transforming (Akt)/Phosphatidylinositol-3 Kinase (PI3K) pathways are being tested for PCa and other cancer subtypes, including the ones described above for treatment implementations [157,158,159]. This evidence concerns the gene AKT1 and cancer.